Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration

AIM: To evaluate the clinical efficacy and systemic safety profile of conbercept in practice on vascular endothelial growth factor (VEGF)-A, VEGF-B, placental (PLGF) levels after intravitreal injections for neovascular age-related macular degeneration (AMD). METHODS: Thirty-five patients (35 eyes) with AMD received treatment pro re nata protocol. Best-corrected visual acuity (BCVA) central retinal thickness (CRT) were detected before injection at 1, 3, 12mo treatment. The serum VEGF-A, PLGF measured by enzyme-linked immunosorbent assay 1 treatments. RESULTS: At baseline, mean BCVA score was 39.89±14.64 letters. scores 51.03±15.78, 56.71±14.38, 52.49±10.16 letters treatment, improvements all significant, respectively (P<0.05). CRT 436.7±141.9 µm. values 335.1±147.8, 301.1±116.5, 312.2±98.22 µm, VEGF-A 1013.8±454.3, 953.1±426.4, 981.5±471.7 pg/mL, VEGF-B 46.93±24.76, 42.99±19.16, 45.32±18.76 these points 251.7±154.9, 241.3±166.7, 245.6±147.2 respectively. Compared did not significantly change (P>0.05). CONCLUSION: Conbercept leads to improvement, however, it does affect treating AMD.